v3.25.2
Consolidated Condensed Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2025
Dec. 31, 2024
Current Assets    
Cash and cash equivalents (Note 7) $ 3,375.9 $ 3,268.4
Short-term investments (Note 7) 170.1 154.8
Accounts receivable, net of allowances of $16.1 (2025) and $14.9 (2024) 14,170.4 11,005.7
Other receivables 3,035.2 2,269.7
Inventories (Note 6) 11,013.8 7,589.2
Prepaid expenses (Note 8) 18,019.8 8,340.5
Other current assets 68.8 111.4
Total current assets 49,854.0 32,739.7
Investments (Note 7) 3,207.4 3,215.9
Goodwill 5,770.5 5,770.3
Other intangibles, net 5,908.3 6,166.3
Deferred tax assets 9,427.4 8,000.6
Property and equipment, net of accumulated depreciation of $12,554.0 (2025) and $11,789.0 (2024) 20,529.7 17,102.4
Other noncurrent assets 6,225.3 5,719.7
Total assets 100,922.6 78,714.9
Current Liabilities    
Short-term borrowings and current maturities of long-term debt 5,723.7 5,117.1
Accounts payable 4,075.7 3,228.6
Employee compensation 1,303.0 2,093.9
Sales rebates and discounts 14,537.4 11,539.3
Dividends payable 1,345.2 1,346.3
Short-term income taxes payable 6,958.0 1,116.4
Other current liabilities 5,076.9 3,935.0
Total current liabilities 39,019.9 28,376.6
Noncurrent Liabilities    
Long-term debt 34,180.1 28,527.1
Accrued retirement benefits (Note 9) 1,344.5 1,300.5
Long-term income taxes payable 5,684.3 4,060.9
Other noncurrent liabilities 2,344.7 2,178.2
Total noncurrent liabilities 43,553.6 36,066.7
Commitments and Contingencies (Note 10)
Eli Lilly and Company Shareholders' Equity    
Common stock 592.0 592.4
Additional paid-in capital 7,089.3 7,439.3
Retained earnings 17,376.2 13,545.0
Employee benefit trust (3,013.2) (3,013.2)
Accumulated other comprehensive loss (Note 11) (3,716.0) (4,321.9)
Cost of common stock in treasury (55.4) (49.5)
Total Eli Lilly and Company shareholders' equity 18,272.9 14,192.1
Noncontrolling interests 76.2 79.5
Total equity 18,349.1 14,271.6
Total liabilities and equity $ 100,922.6 $ 78,714.9